Fig. 7.

Combined therapy is effective in a genetic tumour model. a Schematic diagram of experiments for investigating the combined effect of Y27632 and Dox on tumour growth in a genetically engineered tumour model. b Tumour-bearing MMTV/Neu mice were injected (i.v.) with Y27632 (10 mg kg⁻¹) and/or Dox (5 mg kg⁻¹) as indicated in a. Tumour size was measured at the indicated times. Data are presented as means ± s.e.m (n = 7–9) (left panel) and tumour growth curves of individual mice (right panels). Fractions indicate the number of mice showing complete tumour regression. c Survival of tumour-bearing MMTV/Neu mice following combined therapy (n = 7–9). d, e MMTV/Neu mice bearing tumours were injected (i.v.) with Y27632 and/or Dox. On day 5 after Dox and/or Y27632 treatment, CD8⁺ T cells in tumours were stained with an anti-CD8 antibody. d Representative result. Scale bar, 50 μm. e Number of CD8⁺ T cells per mm². Data are presented as means ± s.d. (n = 4). f On day 5 after Dox and/or Y27632 treatment, single-cell suspensions from spleen were stimulated with rat Neu-derived peptide for 48 h, and IFN-γ production was measured by ELISA. Data are presented as means ± s.d. (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001; significance determined by Kruskal–Wallis test with Bonferroni correction (b), log-rank test (c), or one-way ANOVA with Tukey’s post hoc test (e, f)